Dendreon Corporation
Records under this name other than the patents Dendreon Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,597,894 | Compositions and Methods Employing Alternative Reading Frame Polypeptides for the Treatment of Cancer and Infectious Disease Formerly held In force · High confidence | In force | High confidence | |
| US 7,972,602 | Promiscuous HER-2/NEU CD4 T Cell Epitopes Formerly held In force · High confidence | In force | High confidence | |
| US 8,153,120 | Methods for Inducing a Natural Killer (NK) Cell-Mediated Immune Response and for Increasing NK Cell Activity Formerly held In force · High confidence | In force | High confidence | |
| US 8,361,479 | Promiscuous Pap CD4 T Cell Epitopes Formerly held In force · High confidence | In force | High confidence | |
| US 10,261,091 | Humoral Immune Response Against Tumor Antigens After Treatment with a Cancer Antigen Specific Active Immunotherapy and Its Association with Improved Clinical Outcome Formerly held In force · High confidence | In force | High confidence | |
| US 7,572,444 | Binding Proteins Specific for Human Matriptase Formerly held Term ended Term ended Dec 16, 2025 · High confidence | Term ended | Term ended Dec 16, 2025 | High confidence |
| US RE43,298 | Peptides as NS3-SERINE Protease Inhibitors of Hepatitis C Virus Term ended Term ended Dec 22, 2024 · Low confidence | Term ended | Term ended Dec 22, 2024 | Low confidence |
| US 7,132,398 | Method of Treatment of Hemorrhagic Disease Using a Factor Viia/Tissue Factor Inhibitor Formerly held Term ended Term ended Jan 29, 2024 · High confidence | Term ended | Term ended Jan 29, 2024 | High confidence |
| US 7,413,869 | Method for Determining Potency of Antigenic Presenting Cell Based Vaccines Formerly held Term ended Term ended Nov 12, 2022 · High confidence | Term ended | Term ended Nov 12, 2022 | High confidence |
| US 6,962,795 | Neutrophil inhibitors Formerly held Term ended Term ended Nov 8, 2022 · From the USPTO record | Term ended | Term ended Nov 8, 2022 | From the USPTO record |